SpringWorks Therapeutics to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Core Insights - SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer [3] - The company will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on November 13, 2024 [1] - SpringWorks has developed OGSIVEO® (nirogacestat), the first FDA-approved therapy for adult patients with progressing desmoid tumors [3] Company Overview - SpringWorks applies a precision medicine approach to develop life-changing medicines for patients with severe rare diseases and cancer [3] - The company has a diversified pipeline targeting solid tumors and hematological cancers, with programs at various stages from preclinical to advanced clinical trials [3] - SpringWorks collaborates with industry and academic innovators to enhance its portfolio and create more solutions for patients [3] Event Information - The fireside chat will take place in Boston, Massachusetts at 1:00 p.m. ET [1] - A live webcast of the event can be accessed on the company's website, with a replay available for a limited time afterward [2]